TY - JOUR
T1 - Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease
T2 - A Glimpse into the Horizon
AU - Arnold, Jorge
AU - Idalsoaga, Francisco
AU - Díaz, Luis Antonio
AU - Cabrera, Daniel
AU - Barrera, Francisco
AU - Arab, Juan Pablo
AU - Arrese, Marco
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024/3
Y1 - 2024/3
N2 - Purpose of Review: Metabolic dysfunction–associated steatotic liver disease (MASLD) and its aggressive form, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. Currently, there is no approved pharmacological treatment for MASLD. In this review, we aim to summarize recent data on therapeutic agents under study in phase 2 and 3 trials. Recent Findings: Building on a better understanding of MASLD/MASH pathophysiology, a myriad of drugs has been developed. Recent results from clinical trials show promise, with some candidates demonstrating positive outcomes in phase 3 trials that are predictably expected to be approved in the near future. Notably, resmetirom, a thyroid receptor β agonist, is likely to be approved in 2024. Summary: In the coming years, results from several landmark trials will be available and will likely provide options to prevent progression to cirrhosis and adverse liver outcomes in patients with MASLD/MASH.
AB - Purpose of Review: Metabolic dysfunction–associated steatotic liver disease (MASLD) and its aggressive form, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. Currently, there is no approved pharmacological treatment for MASLD. In this review, we aim to summarize recent data on therapeutic agents under study in phase 2 and 3 trials. Recent Findings: Building on a better understanding of MASLD/MASH pathophysiology, a myriad of drugs has been developed. Recent results from clinical trials show promise, with some candidates demonstrating positive outcomes in phase 3 trials that are predictably expected to be approved in the near future. Notably, resmetirom, a thyroid receptor β agonist, is likely to be approved in 2024. Summary: In the coming years, results from several landmark trials will be available and will likely provide options to prevent progression to cirrhosis and adverse liver outcomes in patients with MASLD/MASH.
KW - Cirrhosis
KW - Fibrosis
KW - MASLD, Metabolic dysfunction–associated steatotic liver disease, Steatohepatitis
KW - Nonalcoholic fatty liver disease
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=85190114116&partnerID=8YFLogxK
U2 - 10.1007/s11901-023-00629-0
DO - 10.1007/s11901-023-00629-0
M3 - Article
AN - SCOPUS:85190114116
SN - 2195-9595
VL - 23
SP - 204
EP - 219
JO - Current Hepatology Reports
JF - Current Hepatology Reports
IS - 1
ER -